Comparative Study of Flunarizine versus Propranolol in the Prophylaxis of Migraine

Authors

  • Mohammad Shamchul Alam Department of Forensic Medicine Chittagong Medical College Chattogram, Bangladesh.
  • ANM Manzurul Kader Chowdhury Department of Forensic Medicine Chittagong Medical College Chattogram, Bangladesh.
  • Sanjida Mamun Department of Clinical Chemistry Epic Healthcare Chattogram, Bangladesh.
  • Touhidur Rahman Department of Neurology Chittagong Medical College Chattogram, Bangladesh.
  • Shemanta Waddadar Department of Neurology Chittagong Medical College Chattogram, Bangladesh.
  • Priyatosh Das Department of Microbiology Chittagong Medical College Chattogram, Bangladesh.
  • Md Ashrafuzzaman Khan National Institute of Neuroscience and Hospital Dhaka, Bangladesh.
  • Nargis Akter Department of Pharmacology and Therapeutics Chandpur Medical College Chandpur, Bangladesh.
  • Muhammad Tayeb Department of Neurology Rangamati Medical College Rangamati, Bangladesh.
  • Md Hassanuzzaman Department of Neurology Chittagong Medical College Chattogram, Bangladesh.

DOI:

https://doi.org/10.3329/cmoshmcj.v23i2.79625

Keywords:

Flunarizine; Migraine; Migraine prophylaxis; Propranolol.

Abstract

Background: Propranolol and flunarizine are the most used first-line drugs in the treatment of migraine. There are limited data regarding the use of prophylactic agents available in Bangladesh. This study aimed to compare the efficacy and tolerability of propranolol and flunarizine in prophylactic management. Materials and methods: This was a open label randomized clinical trial. One hundred and fifty migraine patients were recruited from the Outpatient Department of Neurology and Medicine of Chittagong Medical College Hospital from October, 2017 to September, 2018. They were randomized in a 1:1 ratio to receive either flunarizine (n=75) or propranolol (n=75) once daily. Patients were evaluated for attack frequency, pain severity, duration of headache, disability and drug side effects at 6 weeks and 12 weeks. Results: The Flunarizine group showed a reduction in the mean (±SD) frequency of migraine attacks from 10.58±4.11 to 3.25±2.90 per month, intensity of headache per attack from 8.00±1.33 to 3.63±1.87, number of headache days per month from 11.93±4.12 to 3.25±2.90, duration of headache per episode from 21.18±16.15 to 3.13±3.26 and MIDAS (Migraine Disability Assessment Test) score from 23.15±8.77 to 4.70±4.80. In patients treated with propranolol, a reduction in the mean (±SD) of monthly frequency of migraine attacks from 9.64±3.81 to 4.67±3.15, the intensity of headache per attack from 7.99±1.27 to 4.57±1.48, number of headache days per month from 11.66±4.49 to 4.67±3.15, duration of headache per episode from 24.19±19.33 to 4.85±4.31 and MIDAS score from 23.78±10.48 to 6.51±5.36. The percentage of responders at the study endpoint was 58.2% for propranolol and 80.3% for flunarizine. Both the drugs were well tolerated but adverse effects were more in the propranolol group. Conclusion: Flunarizine was more effective and better tolerable than propranolol in prophylaxis of migraine.

Chatt Maa Shi Hosp Med Coll J; Vol.23 (2); July 2024; Page 24-28

Downloads

Download data is not yet available.

Downloads

Published

2025-03-02

How to Cite

Shamchul Alam, M., Manzurul Kader Chowdhury, A., Mamun, S., Rahman, T., Waddadar, S., Das, P., … Hassanuzzaman, M. (2025). Comparative Study of Flunarizine versus Propranolol in the Prophylaxis of Migraine. Chattagram Maa-O-Shishu Hospital Medical College Journal, 23(2), 24–28. https://doi.org/10.3329/cmoshmcj.v23i2.79625

Issue

Vol. 23 No. 2 (2024)

Section

Original Articles

License

Authors of articles published in CMOSHMC Journal retain the copyright of their articles and are free to reproduce and disseminate their work.

A Copyright and License Agreement -signed and dated by the corresponding author on behalf of all authors -must be submitted with each manuscript submission.